Cordice J W
Division of Thoracic Surgery, Queens Hospital Center, Jamaica, NY 11432.
J Natl Med Assoc. 1990 Apr;82(4):273-9.
One hundred forty patients with carcinoma of the esophagus treated over a 12-year period at Queens Hospital Center were reviewed. Comparable numbers of patients were assigned at random to radiation therapy alone, surgical treatment with radiation, or treatment with combinations of radiation and chemotherapy pre- or postoperatively. Surgical mortality (survival 1 month or less) was 9 patients of 34, or approximately 26%. Mean survival including the early deaths was 7.5 months. Deaths were primarily due to respiratory tract complications, either alone or in combination, with three cases of anastomotic leaks, sepsis, inanition, and progressing carcinoma. Fifty-two patients received radiation therapy alone. Although there were only six deaths (10%) within the first month of treatment, average survival was 8.4 months, only marginally greater than those treated by surgery. Of 13 patients treated with combined radiation and chemotherapy, no deaths occurred within the first month of treatment, but the average survival was only 6.5 months. Of nine patients treated with chemotherapy alone, no deaths occurred within the first month of treatment, but mean survival of this small group was only 4.9 months. Efficacy of chemotherapy and radiation therapy as definitive, adjuvant, or palliative therapy, in spite of recent somewhat optimistic reports, remains to be proven. Exploratory surgery should be retained as an essential staging and therapeutic modality in those patients in whom definite evidence establishing inoperability is lacking; ie, tumor fixation to vital structures, distant metastases, and other medical contraindications to surgery. Endoscopic instrumentation with the yttrium aluminum garnet laser appears to have a future as preliminary to surgery or definitive (palliative) management of obstructing esophageal carcinoma.
回顾了在皇后医院中心12年期间治疗的140例食管癌患者。将数量相当的患者随机分配到单纯放疗组、放疗联合手术治疗组或术前或术后放化疗联合治疗组。手术死亡率(存活1个月或更短时间)为34例中的9例,约为26%。包括早期死亡患者在内的平均生存期为7.5个月。死亡主要是由于呼吸道并发症,单独或合并出现,伴有3例吻合口漏、败血症、营养不良和进展期癌。52例患者接受单纯放疗。虽然在治疗的第一个月内只有6例死亡(10%),但平均生存期为8.4个月,仅略高于手术治疗组。在13例接受放化疗联合治疗的患者中,治疗的第一个月内没有死亡,但平均生存期仅为6.5个月。在9例单纯接受化疗的患者中,治疗的第一个月内没有死亡,但这一小组的平均生存期仅为4.9个月。尽管最近有一些较为乐观的报道,但化疗和放疗作为根治性、辅助性或姑息性治疗的疗效仍有待证实。对于那些缺乏明确证据证明无法手术的患者,即肿瘤与重要结构固定、远处转移和其他手术医学禁忌证的患者,探索性手术应作为必要的分期和治疗方式保留下来。钇铝石榴石激光内镜器械似乎有望作为手术前或梗阻性食管癌的根治性(姑息性)治疗的初步手段。